User: Guest

  



DOMAIN EXPERT ENGAGEMENTS

Number of executives repeatedly engaged by snail & email outreach*

POOL + OUTREACH

6346

Interactions with Platform & by Email *

INTERACTIONS

1015

Unique # Participated *

PARTICIPANTS

190

Responses Validated *

VALIDATIONS

41

* Platform engagements are dynamic. Stats are published quarterly.


  •  CODE

  •  PAGES

  •  DATE

  •  PRICE

    $

  •  DATA EXHIBITS

    125


TABLE OF CONTENTS


   Pages :    | $

   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
  
   Product Definitions and Scope of Study.....I-3  
   Resurgence of the H1N1 Virus.....II-1
A Glimpse of the 2009 H1N1 Pandemic Outbreak, and the Post-Pandemic Phase.....II-1
1$100
   Efforts to Face Potential Pandemics.....II-2
Competitive Scenario.....II-2
1$100
   H1N1 Influenza Vaccines and Manufacturers.....II-31$100
   Key Growth Drivers.....II-4
Consumer Awareness Drives Market Growth in Developed Regions.....II-4
Emerging Economies Offer Strong Potential.....II-4
1$100
   Threat of Antigenic Shift of H1N1 Virus Lingers.....II-5
Key Growth Inhibitors.....II-5
Requirement of Huge Capital and Large-Scale Investments.....II-5
Stringent Regulatory Scenario.....II-5
1$100
   High Competition Lowers Profit Margins.....II-6
Challenges Facing Healthcare Industry in Tackling Pandemics.....II-6
Cumbersome Production Process, New Technologies Come to Rescue.....II-6
Inefficiencies in Vaccine Distribution: A Cause of Concern.....II-6
1$100
   Shorter Lifecycle of Pandemic Influenza.....II-7
Market Trends.....II-7
Antigenic Shift of Virus Unlocks Possibilities for New Seasonal Influenza
  Vaccines.....II-7
Quadrivalent Vaccines – A Whole New Generation of Seasonal Influenza Vaccines.....II-7
1$100
   Innovations in Vaccine Technology to Drive the Effort for a Universal Influenza
  Vaccine.....II-8
Safety Concerns of Influenza Vaccines Abate.....II-8
1$100
   H1N1 Vaccine Sourced from Tobacco Plants.....II-91$100
   Vaccines Market to Witness Robust Increase in Sales Driven by Robust Demand.....II-101$100
   Pneumococcal and Pediatric Multivalent Vaccines Dominate Sales.....II-11
Table 1: Global Vaccines Market by Category (2014): Percentage Breakdown of Value Sales for Adult Booster, Hepatitis, HPV, Influenza, Meningococcal, Pediatric Multivalent, Pneumococcal, Rotavirus, and Shingles (includes corresponding Graph/Chart).....II-11
1$350
   Competitive Scenario.....II-12
Table 2: Global Vaccines Market by Leading Manufacturer (2014): Percentage Market Share Breakdown of Value Sales for Astra Zeneca, GlaxoSmithKline, Merck & Co, Pfizer, Sanofi Pasteur, and Others (includes corresponding Graph/Chart).....II-12
1$350
   Influenza A (H1N1) 2009: The Global Pandemic.....II-13 1$100
   Table 3: Global Death Toll from 2009 A H1N1 (2009-2012) (includes corresponding Graph/Chart).....II-14

Table 4: Mortality Rates of Major Influenza Pandemics Over the Last 100 Years (includes corresponding Graph/Chart).....II-14
1$350
   Economic Impact of H1N1 Pandemic in Retrospect.....II-15
Healthcare & Pharmaceuticals.....II-15
Pork & Pork Products.....II-15
Airlines, Tourism & Hospitality.....II-15
1$100
   Hand Sanitizers.....II-16
H1N1 Influenza Diagnostic Tests.....II-16
2$200
   Table 5: Global Laboratory Rapid Testing by Leading Player (2014): Percentage Market Share Breakdown of Value Sales for Alere, Quidel, Meridian Bioscience, Beckman Coulter/Danaher, OraSure and Others (includes corresponding Graph/Chart).....II-181$350
   Influenza Virus: A Quick Primer.....II-19
Symptoms and Characteristics.....II-19
Types of Influenza.....II-19
Influenza A Virus.....II-19
Influenza A (H1N1) Virus.....II-19
Different Names, in Different Countries.....II-19
1$100
   Symptoms and Risk Factors.....II-20
The Pandemic Life-Cycle.....II-20
1$100
   Seasonal Influenza vis-à-vis H1N1 Flu.....II-21
How H1N1 Is Diagnosed?.....II-21
Prevention and Vaccination Against H1N1.....II-21
Prevention.....II-21
Vaccination.....II-21
1$100
   Vaccine Virus Selection for the 2015-2016 Influenza Season.....II-22
WHO Recommended Virus Strains for Seasonal Influenza Vaccines for Northern
  Hemisphere for 2015-2016.....II-22
1$100
   WHO Recommended Virus Strains for Seasonal Influenza Vaccines for Southern Hemisphere
  for 2015-2016.....II-23
How is H1N1 Vaccine Prepared?.....II-23
Egg-Based Production Process.....II-23
1$100
   Cell Culture-Based Technology.....II-24
Recombinant Technology.....II-24
1$100
   Side Effects of H1N1 Vaccine.....II-25
Primary Targets for Vaccination.....II-25
Adverse Group for Vaccination.....II-25
Treatment for Swine-Flu Infected Individuals.....II-25
1$100
   Anti-Virals for Pandemic (H1N1) 2009 Infection.....II-26
Recommended Dosage of Anti-Virals.....II-26
Rapivab (Peramivir) – The IV Flu Drug.....II-26
1$100
   FDA Approves Rapivab by BioCryst Pharmaceuticals.....II-27
GSK Obtains Marketing Authorization for Quadrivalent Influenza Vaccine in the UK and
  Germany.....II-27
Sanofi Pasteur’s Review Application for Quadrivalent Influenza Vaccine Accepted by
  EU.....II-27
MedImmune Announces FDA Approval of First Quadrivalent Flu Vaccine.....II-27
Novartis Announces FDA Approval for Cell-Culture Derived Vaccine.....II-27
1$100
   GlaxoSmithKline Obtains FDA Approval for FLUARIX® QUADRIVALENT.....II-28
Tianyuan Receives GMP Certification for Influenza and H1N1 Vaccine.....II-28
1$100
   Serum Institute of India to Launch NasoVacS.....II-29
Bharat Biotech to Produce Swine Flu Vaccine in Bulk.....II-29
Vaxart Announces Positive Trials of its H1N1 Tablet Vaccine.....II-29
A*Star and Cytos Biotechnology Collaborate for H1N1 Vaccine.....II-29
VABIOTECH Develops Vaccines for A/H1N1 and A/H5N1 Viruses.....II-29
Focus Diagnostics and 3M Unveil Simplexa™ Test on 3M™ Integrated Cycler.....II-29
1$100
   GSK Acquires GlycoVaxyn AG.....II-30
Baxter to Divest Vero cell Vaccine Technogy and Assets to Nanotherapeutics.....II-30
Novartis to Divest Influenza Vaccines Business to CSL.....II-30
CALIXAR and VirPath Develop Novel Manufacturing Process for Influenza Vaccines.....II-30
bioCSL Restarts Manufacture of Influenza Vaccine.....II-30
Novartis Begins Shipment of Seasonal Influenza Vaccines to US.....II-30
1$100
   bioCSL Obtains Government Contracts for Vaccine Distribution.....II-31
InGen Biosciences Partners with Quidel and Diagnostic Hybrids.....II-31
1$100
   Abbott Laboratories (US).....II-32
CPL Biologicals Pvt. Ltd. (India).....II-32
bioCSL (Australia).....II-32
1$100
   GlaxoSmithKline Plc. (UK).....II-33
MedImmune, LLC. (US).....II-33
1$100
   Novartis AG (Switzerland).....II-34
Sanofi Pasteur, SA (France).....II-34
1$100
   Sinovac Biotech Ltd. (China).....II-35
Zydus Cadila (India).....II-35
2$200
   Table 6: World Recent Past, Current & Future Analysis for H1N1 Vaccines by Geographic Region - US, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed by Annual Sales Figures in US$ Million for the Years 2014 through 2020 (includes corresponding Graph/Chart).....II-371$350
   Table 7: World Historic Review for H1N1 Vaccines by Geographic Region - US, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed by Annual Sales Figures in US$ Million for the Years 2009 through 2013 (includes corresponding Graph/Chart).....II-381$350
   Table 8: World 12-year Analysis for H1N1 Vaccines by Geographic Region - Percentage Breakdown of Dollar Sales for US, Europe, Asia-Pacific, and Rest of World Markets for the Years 2009, 2015 and 2020 (includes corresponding Graph/Chart).....II-391$350
   A. Market Analysis.....III-1
‘Swine Flu’ Strain Returns in the 2013-14 Season.....III-1
1$85
   Major H1N1 Vaccines Available in the US and Canada.....III-2
US FDA-Approved Influenza Vaccines with 2009 H1N1 Virus Strain Indicated for
  2014-2015 Flu Season.....III-2
US FDA-Approved Quadrivalent Vaccines Incorporating H1N1 Strain for Influenza
  Type A and B (2014-15).....III-2
Preparations Authorized by Health Canada for Influenza, including H1N1, in Canada
  (2014-15 season).....III-2
1$85
   Medicare and Medicaid Services for Influenza in the US.....III-3
Table 9: CDC Price List for Pediatric Influenza Vaccines in Basic Package: 2015-2016.....III-3
1$200
   Table 10: CDC Price List for Adult Influenza Vaccines in Basic Package: 2015-2016.....III-4
A Historical Perspective on the H1N1 Pandemic in North America.....III-4
First Case of H1N1 Infection Reported in Mexico.....III-4
Swine Flu Spreads to the United States.....III-4
1$200
   H1N1 Pandemic Linked to Delay in Vaccine Administration.....III-5
Canadian Government’s H1N1 Mass Vaccination Campaign.....III-5
Product Approvals & Launches.....III-5
1$85
   Strategic Corporate Developments.....III-61$85
   Select Key Players.....III-71$85
   B. Market Analytics.....III-8
Table 11: The US Recent Past, Current & Future Analysis for H1N1 Vaccines Analyzed by Annual Sales Figures in US$ Million for the Years 2014 through 2020 (includes corresponding Graph/Chart).....III-8
1$200
   Table 12: The US Historic Review for H1N1 Vaccines Analyzed by Annual Sales Figures in US$ Million for the Years 2009 through 2013 (includes corresponding Graph/Chart).....III-91$200
   A. Market Analysis.....III-10
H3N2 Viruses Predominate in the 2014/15 Season; H1N1 Still in Circulation.....III-10
An Insight into European Influenza Vaccination Scenario.....III-10
Cell-based Vaccine Production Remains Nascent, Egg-based Widely Used.....III-10
1$85
   Major Influenza Vaccines Available in European Union Member Countries.....III-11
Major H1N1 Flu Vaccines Available in Select East European Markets.....III-11
ECDC Proposes New Influenza Vaccination Strategy.....III-11
Immunization of High-Risk Demographics.....III-11
1$85
   Protecting Children, Adolescents, and Young Adults.....III-12
Stemming the Spread of Infection in Public Centers.....III-12
EU Welcomes Quadrivalent LAIVs.....III-12
Safety Concerns of Influenza Vaccines Abate.....III-12
1$85
   Historical Perspective on the H1N1 Pandemic in Europe.....III-13
Product Approvals & Launches.....III-13
1$85
   Strategic Corporate Developments.....III-14
Select Key Players.....III-14
3$255
   B. Market Analytics.....III-17
Table 13: European Recent Past, Current & Future Analysis for H1N1 Vaccines Analyzed by Annual Sales Figures in US$ Million for the Years 2014 through 2020 (includes corresponding Graph/Chart).....III-17
1$200
   Table 14: European Historic Review for H1N1 Vaccines Analyzed by Annual Sales Figures in US$ Million for the Years 2009 through 2013 (includes corresponding Graph/Chart).....III-181$200
   A. Market Analysis.....III-19
2014-15: Deadliest Swine Flu Season in India Since 2009.....III-19
Leading Influenza H1N1 Vaccine Brands Available in Select Asia-Pacific
  Markets.....III-19
1$85
   Historical Perspective on The Outbreak of H1N1 Pandemic In 2009 In Select
  Regions.....III-20
Japan.....III-20
South Korea.....III-20
Taiwan.....III-20
Malaysia.....III-20
1$85
   Philippines.....III-21
New Zealand.....III-21
India.....III-21
China.....III-21
1$85
   Hong Kong.....III-22
Singapore.....III-22
Australia.....III-22
1$85
   Product Approvals & Launches.....III-231$85
   Strategic Corporate Developments.....III-24
Select Key Players.....III-24
2$170
   B. Market Analytics.....III-26
Table 15: Asia-Pacific Recent Past, Current & Future Analysis for H1N1 Vaccines Analyzed by Annual Sales Figures in US$ Million for the Years 2014 through 2020 (includes corresponding Graph/Chart).....III-26
1$200
   Table 16: Asia-Pacific Historic Review for H1N1 Vaccines Analyzed by Annual Sales Figures in US$ Million for the Years 2009 through 2013 (includes corresponding Graph/Chart).....III-271$200
   Market Analysis.....III-28
Table 17: Rest of World Recent Past, Current & Future Analysis for H1N1 Vaccines Analyzed by Annual Sales Figures in US$ Million for the Years 2014 through 2020 (includes corresponding Graph/Chart).....III-28
1$200
   Table 18: Rest of World Historic Review for H1N1 Vaccines Analyzed by Annual Sales Figures in US$ Million for the Years 2009 through 2013 (includes corresponding Graph/Chart).....III-291$200
    
 
 


Sales queries: Sales@StrategyR.com
Research queries: Info411@StrategyR.com